CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project is developing IN-3012, a novel vaccine designed to treat neutralizing antibodies in patients with Haemophilia A. It utilizes the patient's own cells to induce tolerance to factor VIII, aiming to improve treatment outcomes for those who have not responded to standard therapies.
This project will develop and validate IN-3012, a novel tolerogenic vaccine that utilizes a person’s own cells to treat neutralizing antibodies (NA) in Haemophilia A patients who have failed immune tolerance induction (ITI).
Haemophilia A patients are given the blood clotting protein, factor VIII as standard of care.
However, a serious consequence is the development of NA towards factor VIII leading to therapy resistance.
This leads to crippling arthropathy, other morbidities and high mortality…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
